Dr Reddy's Laboratories Other Operating Income or Expenses 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly other operating income or expenses history and growth rate from 2010 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Dr Reddy's Laboratories other operating income or expenses for the quarter ending September 30, 2024 were $0.001B, a 96.59% decline year-over-year.
- Dr Reddy's Laboratories other operating income or expenses for the twelve months ending September 30, 2024 were $0.024B, a 68.57% increase year-over-year.
- Dr Reddy's Laboratories annual other operating income or expenses for 2024 were $0.049B, a 22.22% decline from 2023.
- Dr Reddy's Laboratories annual other operating income or expenses for 2023 were $0.063B, a 198.44% decline from 2022.
- Dr Reddy's Laboratories annual other operating income or expenses for 2022 were $-0.064B, a 592.31% decline from 2021.
Dr Reddy's Laboratories Annual Other Operating Income or Expenses
(Millions of US $) |
| 2024 |
$49 |
| 2023 |
$63 |
| 2022 |
$-64 |
| 2021 |
$13 |
| 2020 |
$57 |
| 2019 |
$28 |
| 2018 |
$12 |
| 2017 |
$16 |
| 2016 |
$13 |
| 2015 |
$15 |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Dr Reddy's Laboratories Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-09-30 |
$1 |
| 2024-06-30 |
$5 |
| 2024-03-31 |
$8 |
| 2023-12-31 |
$10 |
| 2023-09-30 |
$21 |
| 2023-06-30 |
$10 |
| 2023-03-31 |
$-6 |
| 2022-12-31 |
$-11 |
| 2022-09-30 |
$4 |
| 2022-06-30 |
$76 |
| 2022-03-31 |
$-98 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$24 |
| 2021-06-30 |
$7 |
| 2021-03-31 |
$7 |
| 2020-12-31 |
$2 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
$-3 |
| 2019-12-31 |
$3 |
| 2019-09-30 |
$2 |
| 2019-06-30 |
$55 |
| 2019-03-31 |
$5 |
| 2018-12-31 |
$9 |
| 2018-09-30 |
$9 |
| 2018-06-30 |
$4 |
| 2018-03-31 |
$2 |
| 2017-12-31 |
$5 |
| 2017-09-30 |
$2 |
| 2017-06-30 |
$3 |
| 2017-03-31 |
$8 |
| 2016-12-31 |
$3 |
| 2016-09-30 |
$4 |
| 2016-06-30 |
$1 |
| 2016-03-31 |
$4 |
| 2015-12-31 |
$2 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.853B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
